Irvine-based Tarsus Pharmaceuticals Inc. is scheduled to present 11 scientific abstracts at the American Academy of Optometry 2026 Annual Meeting in Anaheim, taking place from tomorrow to Oct. 3.
The abstracts will cover Demodex blepharitis, including patient burden, diagnosis and treatment, outcomes of its Xdemvy treatment, and the prevalence and clinical characteristics of ocular rosacea.
“These 11 abstracts reflect the rapidly evolving understanding of Demodex blepharitis and ocular rosacea—two significant diseases that eye care professionals encounter every day,” Chief Medical Officer Dr. Elizabeth Yeu said in a statement.
Shares in Tarsus were little changed at $76.76 apiece with a $3.6 billion market cap (Nasdaq: TARS).
